RU2008138535A - Химерные антигены вакцин против вируса птичьего гриппа - Google Patents
Химерные антигены вакцин против вируса птичьего гриппа Download PDFInfo
- Publication number
- RU2008138535A RU2008138535A RU2008138535/13A RU2008138535A RU2008138535A RU 2008138535 A RU2008138535 A RU 2008138535A RU 2008138535/13 A RU2008138535/13 A RU 2008138535/13A RU 2008138535 A RU2008138535 A RU 2008138535A RU 2008138535 A RU2008138535 A RU 2008138535A
- Authority
- RU
- Russia
- Prior art keywords
- chimeric
- vaccine antigen
- antigen according
- seq
- influenza virus
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract 23
- 239000000427 antigen Substances 0.000 title claims abstract 21
- 102000036639 antigens Human genes 0.000 title claims abstract 21
- 108091007433 antigens Proteins 0.000 title claims abstract 21
- 241000712461 unidentified influenza virus Species 0.000 title claims abstract 9
- 241000124008 Mammalia Species 0.000 claims abstract 8
- 241000271566 Aves Species 0.000 claims abstract 6
- 239000008267 milk Substances 0.000 claims abstract 6
- 210000004080 milk Anatomy 0.000 claims abstract 6
- 235000013336 milk Nutrition 0.000 claims abstract 6
- 239000000203 mixture Substances 0.000 claims abstract 6
- 241000282887 Suidae Species 0.000 claims abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 4
- 230000002068 genetic effect Effects 0.000 claims abstract 4
- 230000028993 immune response Effects 0.000 claims abstract 4
- 230000001939 inductive effect Effects 0.000 claims abstract 4
- 210000005075 mammary gland Anatomy 0.000 claims abstract 4
- 230000001681 protective effect Effects 0.000 claims abstract 4
- 230000009466 transformation Effects 0.000 claims abstract 4
- 230000009261 transgenic effect Effects 0.000 claims abstract 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract 2
- 241000282412 Homo Species 0.000 claims abstract 2
- 229940124873 Influenza virus vaccine Drugs 0.000 claims abstract 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims abstract 2
- 230000021615 conjugation Effects 0.000 claims abstract 2
- 102000004169 proteins and genes Human genes 0.000 claims abstract 2
- 108090000623 proteins and genes Proteins 0.000 claims abstract 2
- 239000000126 substance Substances 0.000 claims abstract 2
- 230000026683 transduction Effects 0.000 claims abstract 2
- 238000010361 transduction Methods 0.000 claims abstract 2
- 230000003612 virological effect Effects 0.000 claims abstract 2
- 241001465754 Metazoa Species 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/605—MHC molecules or ligands thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
1. Химерный антиген вакцины против вируса птичьего гриппа, характеризующийся содержанием внеклеточного сегмента белка НА из оболочки вируса птичьего гриппа и внеклеточного сегмента молекулы CD154. ! 2. Химерный антиген вакцины по п.1, характеризующийся тем, что в основном содержит аминокислотные последовательности внеклеточного сегмента молекулы CD154 из птиц (SEQ ID NO:6), свиней (SEQ ID NO:8) или человека (SEQ ID NO:4). ! 3. Химерный антиген вакцины по п.1, характеризующийся тем, что в основном содержит аминокислотные последовательности внеклеточного сегмента НА из вирусных подтипов Н5 (SEQ ID NO:2), Н7 (SEQ ID NO:9) и Н9 (SEQ ID NO:10). ! 4. Химерный антиген вакцины по п.1, полученный рекомбинантным путем, синтетическим путем или посредством химической конъюгации. ! 5. Химерный антиген вакцины по п.1, полученный из молока генетически модифицированных млекопитающих. ! 6. Химерный антиген вакцины по п.5, полученный из молока нетрансгенных млекопитающих путем прямой генетической трансформации молочной железы. ! 7. Химерный антиген вакцины по п.6, где прямую генетическую трансформацию молочной железы проводят путем трансдукции аденовирусного вектора. ! 8. Химерный антиген вакцины по п.5, полученный из молока трансгенных млекопитающих. ! 9. Химерный антиген вакцины по п.4, полученный из генетически модифицированных дрожжей. ! 10. Композиция вакцины, способная вызывать защитный иммунный ответ против вируса птичьего гриппа у птиц и млекопитающих, характеризующаяся содержанием химерных антигенов, описанных в пп.1-9. ! 11. Композиция вакцины по п.10, способная вызывать защитный иммунный ответ против вируса птичьего гриппа у птиц, свиней и человека. ! 12. Композиция вакци
Claims (12)
1. Химерный антиген вакцины против вируса птичьего гриппа, характеризующийся содержанием внеклеточного сегмента белка НА из оболочки вируса птичьего гриппа и внеклеточного сегмента молекулы CD154.
2. Химерный антиген вакцины по п.1, характеризующийся тем, что в основном содержит аминокислотные последовательности внеклеточного сегмента молекулы CD154 из птиц (SEQ ID NO:6), свиней (SEQ ID NO:8) или человека (SEQ ID NO:4).
3. Химерный антиген вакцины по п.1, характеризующийся тем, что в основном содержит аминокислотные последовательности внеклеточного сегмента НА из вирусных подтипов Н5 (SEQ ID NO:2), Н7 (SEQ ID NO:9) и Н9 (SEQ ID NO:10).
4. Химерный антиген вакцины по п.1, полученный рекомбинантным путем, синтетическим путем или посредством химической конъюгации.
5. Химерный антиген вакцины по п.1, полученный из молока генетически модифицированных млекопитающих.
6. Химерный антиген вакцины по п.5, полученный из молока нетрансгенных млекопитающих путем прямой генетической трансформации молочной железы.
7. Химерный антиген вакцины по п.6, где прямую генетическую трансформацию молочной железы проводят путем трансдукции аденовирусного вектора.
8. Химерный антиген вакцины по п.5, полученный из молока трансгенных млекопитающих.
9. Химерный антиген вакцины по п.4, полученный из генетически модифицированных дрожжей.
10. Композиция вакцины, способная вызывать защитный иммунный ответ против вируса птичьего гриппа у птиц и млекопитающих, характеризующаяся содержанием химерных антигенов, описанных в пп.1-9.
11. Композиция вакцины по п.10, способная вызывать защитный иммунный ответ против вируса птичьего гриппа у птиц, свиней и человека.
12. Композиция вакцины по п.10, которая может быть превентивно введена животным системным путем или через слизистую.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20060051A CU23576A1 (es) | 2006-02-28 | 2006-02-28 | Antígenos vacunales quiméricos contra el virus de la influenza aviar |
| CU2006-0051 | 2006-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008138535A true RU2008138535A (ru) | 2010-04-10 |
Family
ID=40130782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008138535/13A RU2008138535A (ru) | 2006-02-28 | 2007-02-28 | Химерные антигены вакцин против вируса птичьего гриппа |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20090324644A1 (ru) |
| EP (1) | EP1997831A1 (ru) |
| JP (1) | JP2009528305A (ru) |
| KR (1) | KR20080113217A (ru) |
| CN (1) | CN101421302A (ru) |
| AR (1) | AR059647A1 (ru) |
| AU (1) | AU2007219571A1 (ru) |
| BR (1) | BRPI0708383A2 (ru) |
| CA (1) | CA2638832A1 (ru) |
| CL (1) | CL2007000526A1 (ru) |
| CU (1) | CU23576A1 (ru) |
| MX (1) | MX2008011143A (ru) |
| RU (1) | RU2008138535A (ru) |
| WO (1) | WO2007098718A1 (ru) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3156538C (en) | 2007-11-01 | 2023-12-12 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to eimeria |
| CN102573915B (zh) * | 2009-04-30 | 2015-02-18 | 赛托斯生物技术公司 | 流感血凝素组合物及其用途 |
| TW201738562A (zh) * | 2009-05-28 | 2017-11-01 | 亞培生物股份有限公司 | 體外病原體檢驗技術 |
| KR101262300B1 (ko) * | 2009-10-06 | 2013-05-20 | 헬릭스 주식회사 | 형질전환 식물 유래의 고병원성 조류독감 바이러스 단백질 백신 및 그 제조방법 |
| US9795661B2 (en) | 2009-11-16 | 2017-10-24 | The United States Of America As Represented By The Secretary Of The Navy | TH1/TH2 polarizing vaccines |
| EP3578190A1 (en) | 2013-03-15 | 2019-12-11 | The Board of Trustees of the University of Arkansas | Compositions and methods of enhancing immune responses to enteric pathogens |
| KR101582490B1 (ko) | 2014-04-14 | 2016-01-19 | 아이디바이오 주식회사 | 인플루엔자 바이러스의 다중 아형에 대한 교차 면역반응을 형성하는 신규한 재조합 바이러스 백신 |
| SG11201809686SA (en) | 2016-05-03 | 2018-11-29 | Univ Arkansas | Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same |
| KR101964044B1 (ko) * | 2018-03-14 | 2019-04-02 | 인제대학교 산학협력단 | 재조합 아데노바이러스를 이용한 다가형 인플루엔자 생백신 플랫폼 |
| CN112679586A (zh) * | 2020-12-28 | 2021-04-20 | 乾元浩生物股份有限公司 | H5、h7亚型禽流感病毒基因工程亚单位疫苗及其制备方法与应用 |
| CN114106113B (zh) * | 2021-11-13 | 2024-04-19 | 江苏南农高科技股份有限公司 | 一种表达猪细小病毒vp2蛋白的重组杆状病毒、制备方法及应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2370937T3 (es) | 1993-09-13 | 2011-12-23 | Protein Sciences Corporation | Un método para producir vacunas antigripales polivalentes a base de hemaglutinina. |
| US5762939A (en) | 1993-09-13 | 1998-06-09 | Mg-Pmc, Llc | Method for producing influenza hemagglutinin multivalent vaccines using baculovirus |
| US20020136722A1 (en) * | 1997-06-18 | 2002-09-26 | Heath Andrew William | Vaccination method |
| CU23102A1 (es) * | 2002-10-21 | 2005-12-20 | Ct Ingenieria Genetica Biotech | Método para la producción de proteínas recombinantes en la glándula mamaria de mamíferos no transgénicos |
| EP1951862B1 (en) * | 2005-11-07 | 2013-07-24 | MicroVAX, LLC | Cd40 ligand fusion protein vaccine |
-
2006
- 2006-02-28 CU CU20060051A patent/CU23576A1/es unknown
-
2007
- 2007-02-27 CL CL2007000526A patent/CL2007000526A1/es unknown
- 2007-02-27 AR ARP070100807A patent/AR059647A1/es not_active Application Discontinuation
- 2007-02-28 RU RU2008138535/13A patent/RU2008138535A/ru not_active Application Discontinuation
- 2007-02-28 AU AU2007219571A patent/AU2007219571A1/en not_active Abandoned
- 2007-02-28 KR KR1020087023743A patent/KR20080113217A/ko not_active Application Discontinuation
- 2007-02-28 WO PCT/CU2007/000009 patent/WO2007098718A1/es active Application Filing
- 2007-02-28 EP EP07711103A patent/EP1997831A1/en not_active Withdrawn
- 2007-02-28 CA CA002638832A patent/CA2638832A1/en not_active Abandoned
- 2007-02-28 MX MX2008011143A patent/MX2008011143A/es unknown
- 2007-02-28 BR BRPI0708383-1A patent/BRPI0708383A2/pt not_active Application Discontinuation
- 2007-02-28 CN CNA200780013590XA patent/CN101421302A/zh active Pending
- 2007-02-28 US US12/280,568 patent/US20090324644A1/en not_active Abandoned
- 2007-02-28 JP JP2008556645A patent/JP2009528305A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20080113217A (ko) | 2008-12-29 |
| US20090324644A1 (en) | 2009-12-31 |
| CN101421302A (zh) | 2009-04-29 |
| MX2008011143A (es) | 2008-09-08 |
| AU2007219571A1 (en) | 2007-09-07 |
| WO2007098718A8 (es) | 2008-12-18 |
| BRPI0708383A2 (pt) | 2011-05-24 |
| CU23576A1 (es) | 2010-09-30 |
| AR059647A1 (es) | 2008-04-16 |
| WO2007098718A1 (es) | 2007-09-07 |
| EP1997831A1 (en) | 2008-12-03 |
| CL2007000526A1 (es) | 2009-03-27 |
| JP2009528305A (ja) | 2009-08-06 |
| CA2638832A1 (en) | 2007-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008138535A (ru) | Химерные антигены вакцин против вируса птичьего гриппа | |
| JP7250878B2 (ja) | 新規多価ナノ粒子に基づくワクチン | |
| US10030053B2 (en) | Immunogenic compositions and methods of use thereof | |
| ES2741729T3 (es) | Vectores y construcciones de liberación de antígenos de virus de la gripe | |
| Shi et al. | Immunoprotection against influenza virus H9N2 by the oral administration of recombinant Lactobacillus plantarumNC8 expressing hemagglutinin in BALB/c mice | |
| AU2005319141B2 (en) | Compositions of influenza viral proteins and methods of use thereof | |
| JP2016199557A5 (ru) | ||
| Stepanova et al. | Flagellin-fused protein targeting M2e and HA2 induces potent humoral and T-cell responses and protects mice against various influenza viruses a subtypes | |
| AR061484A1 (es) | Secuencias de adn vectores proteinas y usos de hemaglutinina de gripe aviar | |
| KR101638661B1 (ko) | 백신 벡터 및 면역 반응을 강화시키는 방법 | |
| JP2018504412A5 (ru) | ||
| RS20080174A (en) | Canine influenza virus and related compositions and methods of use | |
| US20090162400A1 (en) | Compositions of influenza viral proteins and methods of use thereof | |
| Pose et al. | Subunit influenza vaccine candidate based on CD154 fused to HAH5 increases the antibody titers and cellular immune response in chickens | |
| US20230015320A1 (en) | Method for preventing or treating influenza virus infection using pharmaceutical composition comprising immunoglobulin fc-fused interleukin-7 fusion protein | |
| JP2016517391A (ja) | オリゴマーインフルエンザ免疫原性組成物 | |
| RU2013119630A (ru) | Вакцинная композиция для борьбы с заражениями эктопаразитами | |
| RU2008138536A (ru) | Химерные вакцинные антигены против вируса классической чумы свиней | |
| Hashem et al. | Subcutaneous immunization with recombinant adenovirus expressing influenza A nucleoprotein protects mice against lethal viral challenge | |
| WO2022135563A1 (zh) | 同时诱导抗多种病毒的免疫应答的方法 | |
| JP2016520534A5 (ru) | ||
| NO20100811L (no) | Subenhetsvaksine for akvakutur | |
| Zeng et al. | Protective effect of a RSV subunit vaccine candidate G1F/M2 was enhanced by a HSP70-Like protein in mice | |
| TW201625298A (zh) | 黏膜疫苗用佐劑 | |
| Zhang et al. | Enhancement of mucosal immune response against the M2eHBc+ antigen in mice with the fusion expression products of LTB and M2eHBc+ through mucosal immunization route |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20100720 |